LONDON, May 27- AstraZeneca said on Friday U.S. regulators would not approve its new drug for high potassium levels at present due to a manufacturing issue, dealing a blow to a product acquired when it bought ZS Pharma for $2.7 billion last year. The British drugmaker said the Food and Drug Administration had issued a so-called complete response letter for ZS-9, or... » Read More
Five stocks, huge yields, great defense against this volatile market.
Earlier this week UBS pharmaceutical analyst Roopesh Patel put out a big 2009 sector outlook research note claiming, "So far, the global economic slowdown has had no noticeable impact — a) U.S. weekly and monthly U.S. prescription trends are stable; b) there also is no meaningfully cautionary commentary from any of the companies...." Well, he might have spoken too soon.
Look for M&A activity—big and small—a pair of breakthrough drugs and the prospect of government price controls.
Does the Food and Drug Administration approve drugs anymore? Or are we seeing the lame-duck leadership at the agency punt any action over to the next administration?
As the market remains focused on Citi and the President-elect's midday cabinet announcement there are a few newsworthy things going on in biopharmaland.
None of my recent pharma-related posts have received nearly as much feedback as I got from my off-the-reservation blog Thursday about Jetgate. The poll drew more than 2,000 votes yesterday, running 4-to-1 in favor of the CEOs of General Motors, Ford and Chrysler flying commercial instead of on private aircraft to and from Washington this week.
Telcos, pharmas and some media stocks present investment opportunities now, according to Fergus O'Sullivan, managing director at Morgan Stanley.
Anglo-Swedish drugmaker AstraZeneca said on Thursday it had been granted a temporary U.S. court order suspending sales of a generic version of its asthma drug Pulmicort by rival Teva.
Over the course of his congressional career the CRP shows that not a single drug company ever broke onto Daschle's top-20 list of contributors. The only healthcare-related firm that pops up is Invacare.
As recession fears continue to spread globally, investment banks like Goldman Sachs scramble to survive — and investment gurus alter their tactics and strategies to roll with the damage. CNBC's expert advisors gave their outlooks on what's coming and what to do about it.
Wall Street has essentially thrown in the towel lately on Amylin Pharmaceuticals. The shares have plummeted from nearly $30 just three months ago to around $7 today.
Cost containment may spell trouble for much of the health-care sector, but Charles Boorady, healthcare providers analyst for Citigroup, says it's likely to spell success for pharmacy benefits managers.
How in the world is Merck gonna rebrand a product it has spent so much time, effort and money gearing toward females so that males will use it, too? I'm not sure, but it'll be interesting to watch if or when MRK wins Food and Drug Administration approval of Gardasil for boys/young men.
Big pharma's got big problems. That should not come as news to anyone who works for, follows or invests in the industry.
US stocks are a safer bet than their foreign counterparts now that the market has found a bottom, Bob Doll, CIO of global equities at BlackRock, told CNBC.
Clermont Wealth Strategies is 'underweight' the entire consumer discretionary sector, which includes retailers, Rob Morgan, market strategist at Clermont Wealth Strategies said.
While on the elliptical at the gym the other night I was watching one network newscast and the person on the machine next to me was watching another one.
Even before the results of the election were official there was already speculation in the blogosphere about who might become the next Commissioner of the Food and Drug Administration under a President Obama.
Drugmaker AstraZeneca, helped by currency effects and cost savings, raised its full-year earnings forecasts on Thursday as third-quarter forecasts beat expectations.
In this Web Extra the traders talk steel and pharma stocks while also paying some attention to the Fed meeting, housing numbers, and delivering a message to Bill Gates.